menu
    • menu

    Company profile for Immunic Therapeutics

    NEW Drugs in Dev: 5
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Immunic is a biotechnology company developing a clinical pipeline of orally administered, small-molecule therapies for chronic inflammatory and autoimmune diseases. Immunic is developing orally administered, small molecule programs: The company’s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, resp...
    Immunic is a biotechnology company developing a clinical pipeline of orally administered, small-molecule therapies for chronic inflammatory and autoimmune diseases. Immunic is developing orally administered, small molecule programs: The company’s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Immunic TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1200 Avenue of the Americas Suite 200 New York, NY 10036
    Telephone
    Telephone
    +1 3322559811
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://imux.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/immunic-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ImmunicInc/

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immunic To Participate In Investor Conferences In March
    Immunic To Participate In Investor Conferences In March

    03 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunic-to-participate-in-investor-conferences-in-march-302702020.html

    PR NEWSWIRE
    03 Mar 2026
    Share Share
    Immunic Reports 2025 Financial Results & Corporate Update
    Immunic Reports 2025 Financial Results & Corporate Update

    26 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunic-inc-reports-year-end-2025-financial-results-and-provides-corporate-update-302697386.html

    PR NEWSWIRE
    26 Feb 2026
    Share Share
    Immunic Closes Oversubscribed Private Placement Financing
    Immunic Closes Oversubscribed Private Placement Financing

    17 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunic-announces-closing-of-oversubscribed-private-placement-financing-302689923.html

    PR NEWSWIRE
    17 Feb 2026
    Share Share
    Immunic Raises $400M to Accelerate Commercialization
    Immunic Raises $400M to Accelerate Commercialization

    13 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunic-announces-oversubscribed-private-placement-of-up-to-usd-400-million-to-accelerate-transformation-into-commercial-stage-company-302687546.html

    PR NEWSWIRE
    13 Feb 2026
    Share Share
    Immunic To Unveil More Phase 2 Vidofludimus Calcium Data
    Immunic To Unveil More Phase 2 Vidofludimus Calcium Data

    04 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunic-to-present-additional-phase-2-calliper-trial-data-for-vidofludimus-calcium-at-the-actrims-forum-2026-reinforcing-its-potential-in-progressive-multiple-sclerosis-302678716.html

    PR NEWSWIRE
    04 Feb 2026
    Share Share
    Immunic Highlights 2025 Accomplishments And Upcoming Milestones
    Immunic Highlights 2025 Accomplishments And Upcoming Milestones

    07 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunic-highlights-2025-accomplishments-and-upcoming-milestones-302653601.html

    PR NEWSWIRE
    07 Jan 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search